# Compare the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy Versus Rosuvastatin Monotherapy in Korean Patients With Left Ventricular Diastolic Dysfunction and Hyperlipidemia

Study · id `cardio:ct-nct04433533` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04433533](<https://clinicaltrials.gov/study/NCT04433533>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04433533

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT04433533. Randomized; no masking; primary purpose treatment. Start 2021-01-06 (actual); primary completion 2023-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT04433533, source copy `cardio:ctgov-nct04433533-2021-01-15`, retrieved 2026-10-31)
- Started: 2021-01-06 (actual) (ClinicalTrials.gov record NCT04433533, source copy `cardio:ctgov-nct04433533-2021-01-15`, retrieved 2026-10-31)
- Primary completion: 2023-06 (anticipated) (ClinicalTrials.gov record NCT04433533, source copy `cardio:ctgov-nct04433533-2021-01-15`, retrieved 2026-10-31)
- Completion: 2023-12 (anticipated) (ClinicalTrials.gov record NCT04433533, source copy `cardio:ctgov-nct04433533-2021-01-15`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT04433533, source copy `cardio:ctgov-nct04433533-2021-01-15`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04433533-2021-01-15`, retrieved 2026-10-31)

## The registry's words

- Brief title: Compare the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy Versus Rosuvastatin Monotherapy in Korean Patients With Left Ventricular Diastolic Dysfunction and Hyperlipidemia
- Condition: Left Ventricular Diastolic Dysfunction
- Condition: Hyperlipidemias
- Intervention (Drug): Rosuvastatin 20
- Intervention (Drug): Rosuvamibe 10/10
- Lead sponsor: Yonsei University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Yonsei University (`cardio:org-yonsei-university`)

## Provenance

Content hash: 12afc78ac0d0f0d00d5dbea620dd19c03d1115b75f76c2ef01450be72b12371d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
